%0 Journal Article %A Konstantin Senkevich %A Sara Bandres-Ciga %A Ziv Gan-Or %A Lynne Krohn %A on behalf of the International Parkinson’s Disease Genomics Consortium (IPDGC) %T Lack of evidence for association of UQCRC1 with Parkinson’s disease in Europeans %D 2020 %R 10.1101/2020.09.04.20188243 %J medRxiv %P 2020.09.04.20188243 %X Recently, a novel variant p.Y314S in UQCRC1 has been implicated as pathogenic in Parkinson’s disease (PD). In the current study, we aimed to examine the association of UQCRC1 with PD in large cohorts of European origin. We examined common and rare genetic variation in UQCRC1 using genome-wide association study data from the International Parkinson Disease Genomics Consortium (IPDGC), including 14,671 cases and 17,667 controls, and whole-genome sequencing data from the Accelerating Medicines Partnership - Parkinson’s disease initiative (AMP-PD), including 1,647 PD patients and 1,050 controls. No common variants were consistently associated with PD, and a variety of burden analyses did not reveal an association between rare variants in UQCRC1 and PD. Therefore, our results do not support a major role for UQCRC1 in PD in the European population, and additional studies in other populations are warranted.Competing Interest StatementZGO has received consulting fees from Lysosomal Therapeutics Inc., Idorsia, Prevail Therapeutics, Denali, Ono Therapeutics, Neuron23, Handl Therapeutics, Deerfield and Inception Sciences (now Ventus). None of these companies were involved in any parts of preparing, drafting and publishing this study. Other authors have no additional disclosures to report.Funding StatementWe thank the participants for contributing to the study. We would like to also thank all members of the International Parkinson Disease Genomics Consortium (IPDGC). For a complete overview of members, acknowledgements and funding, please see http://pdgenetics.org/partners. This work was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. This research was supported in part by the Intramural Research Program of the NIH, National institute on Aging. KS is supported by a post-doctoral fellowship from the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL). ZGO is supported by the Fonds de recherche du Quebec - Sante (FRQS) Chercheurs-boursiers award, in collaboration with Parkinson Quebec, and by the Young Investigator Award by Parkinson Canada.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board (McGill University Health Center Research Ethics Board - MUHC REB) approved the study protocolsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code used in the current study is available at our GitHub. https://github.com/ipdgc/IPDGC-Trainees/blob/master/UQCRC1_IPDGC_trainee.md %U https://www.medrxiv.org/content/medrxiv/early/2020/09/07/2020.09.04.20188243.full.pdf